Literature DB >> 11001913

Abolished angiogenicity and tumorigenicity of Burkitt lymphoma by interleukin-10.

L Cervenak1, L Morbidelli, D Donati, S Donnini, T Kambayashi, J L Wilson, H Axelson, E Castaños-Velez, H G Ljunggren, R D Malefyt, H J Granger, M Ziche, M T Bejarano.   

Abstract

Because of its immunosuppressive properties, interleukin-10 (IL-10) is thought to play an important role in a number of human disease states, including inflammation, autoimmunity, and transplant rejection. In this study, we demonstrate that introduction of human or viral IL-10 genes into Burkitt's lymphoma cells markedly reduced their ability to grow as subcutaneous (sc) tumors in SCID mice. In vivo assays for angiogenesis revealed an inhibition of the angiogenic capacity of the IL-10-transfected lines. Recombinant human IL-10 abolished and viral IL-10 reduced vascular endothelial growth factor (VEGF)-165-induced neovascularization. Furthermore, IL-10 blocked the VEGF- and fibroblast growth factor (FGF)-2-induced proliferation of microvascular endothelial cells in vitro. The current observations suggest a direct role for IL-10 in the prevention of angiogenesis in human lymphoid malignancies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11001913

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

Review 1.  Angiogenesis in hematologic malignancies and its clinical implications.

Authors:  Renchi Yang; Zhong Chao Han
Journal:  Int J Hematol       Date:  2002-04       Impact factor: 2.490

2.  Absence of PAF actions increases angiogenesis.

Authors:  Marina Ziche
Journal:  Br J Pharmacol       Date:  2004-03-15       Impact factor: 8.739

3.  Lister strain vaccinia virus with thymidine kinase gene deletion is a tractable platform for development of a new generation of oncolytic virus.

Authors:  J Hughes; P Wang; G Alusi; H Shi; Y Chu; J Wang; V Bhakta; I McNeish; A McCart; N R Lemoine; Y Wang
Journal:  Gene Ther       Date:  2015-04-16       Impact factor: 5.250

4.  Functional validation of genes implicated in lymphomagenesis: an in vivo selection assay using a Myc-induced B-cell tumor.

Authors:  Duonan Yu; Diana Cozma; Andrea Park; Andrei Thomas-Tikhonenko
Journal:  Ann N Y Acad Sci       Date:  2005-11       Impact factor: 5.691

5.  T-cell Expression of IL10 Is Essential for Tumor Immune Surveillance in the Small Intestine.

Authors:  Kristen L Dennis; Abdulrahman Saadalla; Nichole R Blatner; Shuya Wang; Vysak Venkateswaran; Fotini Gounari; Hilde Cheroutre; Casey T Weaver; Axel Roers; Nejat K Egilmez; Khashayarsha Khazaie
Journal:  Cancer Immunol Res       Date:  2015-04-08       Impact factor: 11.151

6.  Inactivation of Myc in murine two-hit B lymphomas causes dormancy with elevated levels of interleukin 10 receptor and CD20: implications for adjuvant therapies.

Authors:  Duonan Yu; Michael Dews; Andrea Park; John W Tobias; Andrei Thomas-Tikhonenko
Journal:  Cancer Res       Date:  2005-06-15       Impact factor: 12.701

7.  Polymorphisms of interleukin-10 promoter are not associated with prognosis of advanced gastric cancer.

Authors:  Jie Liu; Bao Song; Jia-Lin Wang; Zeng-Jun Li; Wan-Hu Li; Zhe-Hai Wang
Journal:  World J Gastroenterol       Date:  2011-03-14       Impact factor: 5.742

Review 8.  A pooled analysis of the IL-10-1082 A/G polymorphism and the nasopharyngeal carcinoma susceptibility.

Authors:  Liping Ma; Shan Li; Yu Lu; Xiaolian Zhang; Jiangyang Zhao; Xue Qin
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-12-31       Impact factor: 2.503

9.  Altered cutaneous immune parameters in transgenic mice overexpressing viral IL-10 in the epidermis.

Authors:  Wanhong Ding; Stefan Beissert; Liang Deng; Edward Miranda; Christopher Cassetty; Kristina Seiffert; Kristina L Campton; Zhengmin Yan; George F Murphy; Jeffrey A Bluestone; Richard D Granstein
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

10.  Interleukin 10 gene -1082A/G polymorphism is associated with osteosarcoma risk and poor outcomes in the Chinese population.

Authors:  Yan Cui; Jia-Jun Zhu; Cheng-Bin Ma; Kai Cui; Feng Wang; Sheng-Hui Ni; Zhi-Yu Zhang
Journal:  Tumour Biol       Date:  2015-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.